Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
CorrectionCorrection

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

The Journal of Rheumatology December 2019, 46 (12) 1648-1649; DOI: https://doi.org/10.3899/jrheum.171361.C1
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol 2019;46:7–18.

In Table 1, Phase II, NCT01469013 is mentioned twice. The second occurrence is unnecessary.

In the Results section, page 9, last paragraph, the first sentence should read as follows: “The herpes zoster IR was significantly higher for 4 mg compared to placebo (4.3 vs 1.0) and was numerically higher for 4 mg compared to 2 mg in 2 mg-4 mg–extended.” Bold face indicates words added for clarity.

Table 4. Adverse events (AE) detail.

  • Three AE (EAIR ≥ 0.2) and their data have been added under the category “Temporary interruption because of AE ≥ 0.2 EAIR for 4 mg–treated patients in placebo-4 mg, n (EAIR).” See below.

  • Under the category “Permanent discontinuation because of AE ≥ 0.2 EAIR for 4 mg–treated patients in placebo-4 mg, n (EAIR),” in the row for infections and infestations, under the 2mg-4mg-extended set, for baricitinib 4 mg, the p value is < 0.05, indicating significance.

Table 5. The corrected table is below. Changes are indicated in bold face.

  • HDL numbers have been corrected.

  • Units for hemoglobin were corrected to g/dl.

  • Hemoglobin < 10 g/dl: the corrected values for baricitinib 2 mg and baricitinib 4 mg under the Placebo-2 mg–4 mg set are 33/462 (7.1) and 35/467 (7.5), respectively.

  • In the Placebo-4 mg set, under Baricitinib 4 mg, the corrected values for ALT ≥ 3× ULN are 15/987 (1.5), and for ALT ≥ 5× ULN, 7/988 (0.7).

View this table:
  • View inline
  • View popup
Table 4.

Additional data.

View this table:
  • View inline
  • View popup
Table 5 (Corrected).

Changes in selected laboratory values and clinical chemistry (weeks 0–24).a

View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 46, Issue 12
1 Dec 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
The Journal of Rheumatology Dec 2019, 46 (12) 1648-1649; DOI: 10.3899/jrheum.171361.C1

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
The Journal of Rheumatology Dec 2019, 46 (12) 1648-1649; DOI: 10.3899/jrheum.171361.C1
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Correction
  • Correction
  • Enthesitis: Myth or Reality?
Show more Correction

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire